The UK and US have agreed to a important trade agreement that will guarantee zero levies on British pharmaceutical exports going into the American market.
Agreement Details of the Pact
As part of the deal, the UK has committed to raise expenditure on pharmaceuticals through the National Health Service (NHS). This pledge guarantees that duties on these crucial goods will remain at zero for a timeframe of the next three years.
This agreement is in response to recent warnings to significantly raise duties on patented pharmaceutical products, with increases discussed reaching 100%.
"This deal with the Britain bolsters the worldwide climate for innovative medicines and brings much-needed fairness to transatlantic drug exports," a statement declared.
Economic Importance
Drugs are one of the UK's largest goods shipped to the America, which is clearly the largest buyer for large companies like GSK and AstraZeneca.
Trade data indicate that in the one-year period to the end of last September, the UK exported pharmaceutical products totaling over eleven billion pounds to the US. This value accounted for 17.4% of total UK exports in that span.
"This deal protects work, increases capital expenditure and facilitates the UK to establish itself as a international leader for life sciences," a government official commented.
Specific British Pledges
The pact involves several notable pledges from the UK:
- Revised Affordability Limit: The UK will lift the affordability limit at which it considers new treatments to be unaffordable by 25%.
- Increased NHS Spending: There is a aim to raise overall NHS spending on treatments from 0.3% of the national economy to 0.6 percent over the following ten-year period.
- Payback Limit: The sum pharmaceutical firms must return to the NHS to stay within budget will be restricted at 15%. Previously, rebates were more than twenty percent.
Broader Context
This agreement comes amid a ongoing tension between the pharmaceutical industry and the UK government over medicine costs and approval rates.
These tensions were exacerbated by assertions that US patients were paying significantly more for the same drugs than patients in the Britain and the EU.
Recently, several major pharmaceutical investments in the UK have been halted or cancelled, while substantial funding commitments have been announced toward US facilities.
A senior figure stated that the NHS had to spend more on drugs, noting that its expenditure on drugs had declined as a share of its total funding over the previous ten-year period.
